Of the various drugs currently suggested for the treatment of malignant hyperpyrexia, dantrolene sodium was the most effective in reversing and inhibiting drug induced contractures in vitro, both in normal muscle and in muscle from patients who are susceptible to malignant hyperpyrexia. It is suggested that dantrolene sodium is the drug of choice for lowering the raised myoplasmic calcium concentrations in malignant hyperpyrexia.
References
1.
ChyatteS. B., and BirdsongJ. H. (1971): “The Use of Dantrolene Sodium in Disorders of the Central Nervous System”, Sth. Med. J. Nashville, 64, 830.
2.
ChyatteS. B., BirdsongJ. H., and BergmanB. A. (1971): “The Effect of Dantrolene Sodium on Spasticity and Motor Performance in Hemiplegia”, Sth. Med. J. Nashville, 64, 180.
3.
EllisF. R., ClarkeI. M. C., AppleyardT. N., and DinsdaleR. C. W. (1974): “Malignant Hyperpyrexia Induced by Nitrous Oxide and Treated with Dexamethasone”, Brit. Med. J., 4, 270.
4.
EllisK. O., and BryantS. H. (1972): “Excitation-contraction Uncoupling in Skeletal Muscle by Dantrolene Sodium”, Naunyn-Schmiedeberg's Arch. Exp. Path. Pharmak., 274, 107.
5.
EllisR. H., SimpsonP. J., TathamP. F., LeightonM., and WilliamsJ. (1975): “The Cardiovascular Effects of Dantrolene Sodium in Dogs”, Anaesthesia, 30, 318.
6.
HarrisonG. G. (1975): “Control of Malignant Hyperpyrexia Syndrome in M.H.S. Swine by Dantrolene Sodium”, Brit. J. Anaesth., 47, 62.
7.
KalowW., BrittB. A., TerreauM. E., and HaistC. (1970): “Metabolic Error of Muscle Metabolism after Recovery from Malignant Hyperthermia”, Lancet, 2, 895.
8.
MouldsR. F. W., and DenboroughM. A. (1972): “Procaine in Malignant Hyperpyrexia”, Brit. Med. J., 4, 526.
9.
MouldsR. F. W., and DenboroughM. A. (1974a): “Biochemical Basis of Malignant Hyperpyrexia”, Brit. Med. J., 2, 241.
10.
MouldsR. F. W., and DenboroughM. A. (1974b): “Identification of Susceptibility to Malignant Hyperpyrexia”, Brit. Med. J., 2, 245.
11.
NobleW. H., McKeeD., and GatesB. (1973): “Malignant Hyperthermia with Rigidity Successfully Treated with Procainamide”, Anesthesiology, 39, 450.
